Losartan Potassium Tablet, Film Coated
Product Images NDC 63187-296

Product Visual Gallery

This gallery contains 8 technical images submitted to the FDA as part of the official labeling for Losartan Potassium (NDC 63187-296). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Proficient Rx Lp, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

63187-296-90 (Losartan50mg30s)

Losartan Potassium 50 mg tablets label showing a 30 count package. Each film-coated, oval-shaped tablet contains 50 mg losartan potassium USP. The label includes the Proficient Rx logo, product ID RL029630, manufacturer Hetero Labs Limited, storage instructions at 20°-25°C (68°-77°F), and warnings to keep medication out of reach of children. NDC 63187-296-30 is displayed along with lot and expiration placeholders.*

FDA Label Image

Losartanaddress1 (Losartanaddress1)

FDA Label Image

Losartanaddress2 (Losartanaddress2)

FDA Label Image

Losartanfigure1 (Losartanfigure1)

A line graph comparing the percentage of patients with a primary endpoint over time between Losartan potassium and Atenolol. The x-axis marks study months from 0 to 60, and the y-axis shows percentage from 0 to 16%. The graph includes an adjusted risk reduction of 13% with a p-value of 0.021.*

FDA Label Image

Losartanfigure2 (Losartanfigure2)

A line graph comparing the percentage of patients with fatal or non-fatal stroke over study months between Losartan Potassium and Atenolol treatments. The graph shows Losartan Potassium associated with a lower percentage of stroke patients over time, indicating an adjusted risk reduction of 25% with a significance level of p=0.001.*

FDA Label Image

Losartanfigure3 (Losartanfigure3)

A figure showing primary endpoint event rates and hazard ratios for Losartan Potassium versus Atenolol across demographic subgroups including age, gender, race, ISH, diabetes, and history of cardiovascular disease. The chart compares event rates (%) and hazard ratios with 95% confidence intervals for primary composite endpoints and fatal/non-fatal stroke outcomes among patient groups.*

FDA Label Image

Losartanfigure4 (Losartanfigure4)

A line graph comparing the percentage of patients with an event over 48 months between Losartan Potassium and placebo groups. The x-axis represents time in months, and the y-axis shows the percentage of patients with the event. The graph indicates risk reduction with Losartan Potassium versus placebo.*

FDA Label Image

Losartanstructure (Losartanstructure)

Chemical structure diagram of Losartan Potassium, showing its molecular arrangement including a chlorothiazole group, biphenyl group, and potassium ion (K+).*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.